The Stockholm3 test is an innovative blood test for the early detection of aggressive prostate cancer. Unlike the conventional PSA test, it combines several diagnostic parameters, enabling a significantly more precise risk assessment.

How does the test work?
The Stockholm3 test is based on a combination of:

Five biomarkers in the blood

Genetic risk factors

Clinical information such as age, family history and previous findings

This data is evaluated using an algorithm-based model to determine the individual risk of aggressive prostate cancer as accurately as possible.

What advantages does the test offer?
Early detection of aggressive forms of cancer

Reduction of unnecessary biopsies through more targeted selection of high-risk patients

Higher diagnostic accuracy compared to PSA testing alone

Supporting well-founded treatment decisions

Who is the test suitable for?
The Stockholm3 test is aimed at:

Men between 50 and 70 years

Men with elevated PSA levels

Men with a family history of prostate cancer

Men who are unsure about the need for a biopsy

Aim of the test
Through improved risk assessment, the Stockholm3 test is intended to help detect prostate cancer early and specifically, avoid unnecessary interventions, and maintain the quality of life of affected men in the long term.